|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FITM2 |
Gene summary for FITM2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FITM2 | Gene ID | 128486 |
| Gene name | fat storage inducing transmembrane protein 2 | |
| Gene Alias | C20orf142 | |
| Cytomap | 20q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q8N6M3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 128486 | FITM2 | HCC1_Meng | Human | Liver | HCC | 2.58e-35 | 3.85e-02 | 0.0246 |
| 128486 | FITM2 | HCC2_Meng | Human | Liver | HCC | 1.15e-03 | 1.57e-02 | 0.0107 |
| 128486 | FITM2 | HCC1 | Human | Liver | HCC | 2.01e-25 | 3.72e+00 | 0.5336 |
| 128486 | FITM2 | HCC2 | Human | Liver | HCC | 1.52e-28 | 3.08e+00 | 0.5341 |
| 128486 | FITM2 | HCC5 | Human | Liver | HCC | 4.17e-35 | 2.32e+00 | 0.4932 |
| 128486 | FITM2 | S014 | Human | Liver | HCC | 4.70e-11 | 4.60e-01 | 0.2254 |
| 128486 | FITM2 | S015 | Human | Liver | HCC | 3.65e-17 | 7.33e-01 | 0.2375 |
| 128486 | FITM2 | S016 | Human | Liver | HCC | 6.51e-21 | 6.43e-01 | 0.2243 |
| 128486 | FITM2 | S028 | Human | Liver | HCC | 2.16e-04 | 1.58e-01 | 0.2503 |
| 128486 | FITM2 | S029 | Human | Liver | HCC | 2.00e-03 | 1.56e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00160329 | Breast | Precancer | viral process | 58/1080 | 415/18723 | 3.42e-10 | 3.16e-08 | 58 |
| GO:00190589 | Breast | Precancer | viral life cycle | 47/1080 | 317/18723 | 2.42e-09 | 1.99e-07 | 47 |
| GO:00444039 | Breast | Precancer | biological process involved in symbiotic interaction | 42/1080 | 290/18723 | 3.40e-08 | 2.11e-06 | 42 |
| GO:00521269 | Breast | Precancer | movement in host environment | 29/1080 | 175/18723 | 2.59e-07 | 1.28e-05 | 29 |
| GO:00517019 | Breast | Precancer | biological process involved in interaction with host | 31/1080 | 203/18723 | 6.52e-07 | 2.71e-05 | 31 |
| GO:00507929 | Breast | Precancer | regulation of viral process | 27/1080 | 164/18723 | 7.59e-07 | 3.05e-05 | 27 |
| GO:00444099 | Breast | Precancer | entry into host | 25/1080 | 151/18723 | 1.74e-06 | 6.19e-05 | 25 |
| GO:00467189 | Breast | Precancer | viral entry into host cell | 24/1080 | 144/18723 | 2.46e-06 | 8.35e-05 | 24 |
| GO:00190799 | Breast | Precancer | viral genome replication | 22/1080 | 131/18723 | 5.63e-06 | 1.66e-04 | 22 |
| GO:00439039 | Breast | Precancer | regulation of biological process involved in symbiotic interaction | 15/1080 | 72/18723 | 1.23e-05 | 3.17e-04 | 15 |
| GO:19039009 | Breast | Precancer | regulation of viral life cycle | 23/1080 | 148/18723 | 1.31e-05 | 3.30e-04 | 23 |
| GO:00523727 | Breast | Precancer | modulation by symbiont of entry into host | 12/1080 | 49/18723 | 1.61e-05 | 3.93e-04 | 12 |
| GO:00465964 | Breast | Precancer | regulation of viral entry into host cell | 11/1080 | 42/18723 | 1.83e-05 | 4.35e-04 | 11 |
| GO:19039014 | Breast | Precancer | negative regulation of viral life cycle | 7/1080 | 25/18723 | 4.00e-04 | 5.42e-03 | 7 |
| GO:0046597 | Breast | Precancer | negative regulation of viral entry into host cell | 6/1080 | 21/18723 | 9.31e-04 | 1.06e-02 | 6 |
| GO:00450697 | Breast | Precancer | regulation of viral genome replication | 13/1080 | 85/18723 | 1.12e-03 | 1.23e-02 | 13 |
| GO:00485255 | Breast | Precancer | negative regulation of viral process | 12/1080 | 92/18723 | 6.51e-03 | 4.51e-02 | 12 |
| GO:001603214 | Breast | IDC | viral process | 75/1434 | 415/18723 | 1.98e-12 | 4.02e-10 | 75 |
| GO:001905814 | Breast | IDC | viral life cycle | 61/1434 | 317/18723 | 1.61e-11 | 2.77e-09 | 61 |
| GO:001907914 | Breast | IDC | viral genome replication | 32/1434 | 131/18723 | 2.82e-09 | 2.46e-07 | 32 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FITM2 | SNV | Missense_Mutation | c.645N>A | p.Asn215Lys | p.N215K | Q8N6M3 | protein_coding | deleterious(0) | benign(0.089) | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| FITM2 | insertion | Frame_Shift_Ins | novel | c.72_73insGCGAACCTCGTCTCTTCTAAAA | p.Pro25AlafsTer134 | p.P25Afs*134 | Q8N6M3 | protein_coding | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| FITM2 | insertion | Frame_Shift_Ins | novel | c.70_71insAGCCTGTCCAACA | p.Leu24GlnfsTer132 | p.L24Qfs*132 | Q8N6M3 | protein_coding | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| FITM2 | SNV | Missense_Mutation | rs370245406 | c.487N>A | p.Ala163Thr | p.A163T | Q8N6M3 | protein_coding | tolerated(0.26) | benign(0.04) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| FITM2 | SNV | Missense_Mutation | rs771219892 | c.253N>A | p.Gly85Ser | p.G85S | Q8N6M3 | protein_coding | tolerated(0.43) | possibly_damaging(0.593) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| FITM2 | SNV | Missense_Mutation | novel | c.118N>A | p.Glu40Lys | p.E40K | Q8N6M3 | protein_coding | deleterious(0.02) | possibly_damaging(0.631) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FITM2 | SNV | Missense_Mutation | novel | c.581N>T | p.Ala194Val | p.A194V | Q8N6M3 | protein_coding | deleterious(0) | possibly_damaging(0.611) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| FITM2 | SNV | Missense_Mutation | novel | c.152N>G | p.Asn51Ser | p.N51S | Q8N6M3 | protein_coding | tolerated(0.42) | benign(0.112) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| FITM2 | SNV | Missense_Mutation | rs755374181 | c.539N>A | p.Arg180Gln | p.R180Q | Q8N6M3 | protein_coding | tolerated(0.4) | possibly_damaging(0.849) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| FITM2 | SNV | Missense_Mutation | novel | c.499G>A | p.Val167Ile | p.V167I | Q8N6M3 | protein_coding | tolerated(0.19) | benign(0.038) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |